利妥昔单抗治疗伴有脱髓鞘疾病的强直性脊柱炎患者：病例报告及文献复习。
Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.
机构信息
Department of Medicine, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.
出版信息
Clin Rheumatol. 2012 Aug;31(8):1259-61. doi: 10.1007/s10067-012-2002-8. Epub 2012 May 27.
PMID:22644089
Abstract
Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.
摘要
肿瘤坏死因子抑制剂（TNFI）是一种新型治疗方法，用于治疗强直性脊柱炎（AS）。脱髓鞘疾病是 TNFI 的一种罕见但严重的并发症。我们报告了 1 例 AS 患者，因 TNFI 继发脱髓鞘疾病，经利妥昔单抗治疗后成功。
Zotero 插件